Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...

Using a single-cell sequencing technique, Brazilian researchers have created the first cell atlas of focal cortical dysplasia (FCD), a malformation of the cerebral cortex that leads to drug-resistant ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...

Ramakrishnan, a distinguished structural biologist and Nobel Laureate in Chemistry (2009), is renowned for his groundbreaking ...

Discover how mRNA-based blood clots offer a promising new treatment for osteoarthritis, potentially surpassing traditional ...

Most people associate sunburns with DNA damage -- it's what we've been taught in textbooks and by dermatologists for years.

Large-cap Health Care company Moderna has logged a 0.6% change today on a trading volume of 6,193,314. The average volume for ...